MedPath

Feasibility, Acceptability, and Preliminary Effects of ISTDP for Personality Disorders in a Specialized Psychiatric Clinic

Not Applicable
Conditions
Personality Disorder
Interventions
Behavioral: ISTDP
Registration Number
NCT06591754
Lead Sponsor
Karolinska Institutet
Brief Summary

The primary objective of this study is to evaluate the feasibility and acceptability of a 25-week combined group and individual therapy program using Intensive Short-Term Dynamic Psychotherapy (ISTDP) for patients diagnosed with personality disorders. The secondary objective is to investigate preliminary effects of the treatment in terms of reducing symtoms of depression, anxiety and emotion regulation difficulties.

Detailed Description

The investigators vill investigate a 25-week treatment with ISTDP that consists of both weekly group- and individual therapy for patients diagnosed with personality disorder in a psychiatric clinic specialized on depression, anxiety and PTSD. The feasibility and acceptability and preliminary effects will be evaluated using a within-group design with repeated measures and qualitative interviews. Patients will be recruited from the clinic and the main inclusion criteria is that the patient have a personality disorder diagnosis.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
34
Inclusion Criteria

Personality disorder diagnosis (Clinical assessment using STIP-5) Speaks Swedish fluently

Exclusion Criteria

Autism or intellectual disability Borderline, antisocial or narcissistic personality disorder diagnosis Need for interpreter Urgent social misery Psychotic disorder High suicidality

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ISTDPISTDPISTDP combined group- and individual therapy
Primary Outcome Measures
NameTimeMethod
Patients experience of, and satisfaction with, the treatment assessed through qualitative interviewsImmediately after treatment completion

Patients experience of, and satisfaction with, the treatment assessed through qualitative interviews

Depression symtomsBaseline, weekly throughout treatment, immediately after treatment completion and 6-month follow-up

Depression symtoms will be measured with Patient Health Questionnaire (PHQ-9; (Kroenke et al., 2001)

Participants satisfaction with treatment assessed with the Client Satisfaction Questionnaire (CSQ-8)Immediately after treatment completion (25 weeks)

Participants satisfaction with treatment assessed with the Client Satisfaction Questionnaire (CSQ-8)

Adverse events related to the treatmentFrom start of treatment up to. 6 month follow up.

Adverse events related to the treatment

Number of individual sessions attended during the treatmentThroughout the treatment period, up to 25 weeks

Number of individual sessions attended during the treatment

Number of group sessions attended during the treatmentThroughout the treatment period, up to 25 weeks

Number of group sessions attended during the treatment

Number of dropoutsThroughout the treatment period, up to 25 weeks

Number of dropouts

Total number of sessions attended during the treatmentThroughout the treatment period, up to 25 weeks

Total number of sessions attended during the treatment

Secondary Outcome Measures
NameTimeMethod
Fear of negative emotionsChange from baseline to post-treatment (25 weeks) and follow up 6 months after treatment.

Fear of negative emotion scale (Gilbert et al., 2014) for assessing fear and avoidance of negative feelings.

Anxiety symtomsChange from baseline to immediately after treatment completion (25 weeks) and follow up 6 months after treatment.

Generalized Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006) for assessing anxiety symtoms.

Emotions regulation difficultiesChange from baseline to immediately after treatment completion (25 weeks) and follow up 6 months after treatment.

Difficulties in Emotion Regulation Scale (DERS-16; Bjureberg et al., 2016) for assessing difficulties with emotions regulation.

Severity of personality disorderChange from baseline to immediately after treatment completion (25 weeks) and follow up 6 months after treatment.

Levels of Personality Functioning Brief Form (LPFS-BF; Weekers et al., 2019) for assessing degree of personality disorder.

Symtoms of Borderline Personality disorderChange from baseline to immediately after treatment completion (25 weeks) and follow up 6 months after treatment.

Borderline Symtom List (BLS-23; Bohus et al., 2008) for assessing symtoms of Borderline personality disorder.

Quality of lifeChange from baseline to immediately after treatment completion (25 weeks) and follow up 6 months after treatment.

EuroQol-5D (EQ5D; Balestroni, Gianluigi, \& Bertolotti, 2015) for assessing quality of life.

Working allianceWeekly throughout treatment , up to 25 weeks

Session Alliance Inventory (SAI; Falkenström et al., 2015) for assessing the working alliance with the therapist

Emotional activation during therapyWeekly throughout treatment, up to 25 weeks

Emotional Experience Self Report (Fisher et al., 2016) for assessing the degree of emotional activation during the session.

Trial Locations

Locations (1)

Affektiva, ångest och traumaprogrammet, Psykiatri Sydväst

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath